C4 Therapeutics, Inc. Common Stock (CCCC) Stock
NASDAQ · CCCC
3.30
Fundamentals
Market cap
$417.06M
Price / Earnings ratio
-4.1x
Price / Sales ratio
11.9x
Price / Book ratio
1.7x
Return on assets
-0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About C4 Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees104
CEOMr. Andrew J. Hirsch M.B.A.
IPO DateOct 2, 2020
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew J. Hirsch M.B.A. | CEO, President & Director | 1971 |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 1951 |
| Ms. Kendra R. Adams | Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | 1977 |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer | 1962 |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Ms. Courtney Solberg | Senior Manager of Investor Relations | — |
| Ms. Kelly A. Schick | Chief People Officer | 1980 |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances & Business Development | — |
| Dr. Christopher Nasveschuk | Senior Vice President of Chemistry | — |
| Mr. Roy Pollock Ph.D. | Senior Vice President of Biological Sciences | — |
Fundamentals
Valuation
Market cap$417.06M
Price-to-sales ratio11.90
Price-to-book value1.69
Price-earnings ratio-4.10
Return on Equity-51.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.91
Income Statement
Average volume1,916,844
EBITDA$-95.55M
1 year high (52w)$5.17
1 year low (52w)$1.69
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



